Immunoglobulin antithymocyte (Immunoglobulinum antithymocytarum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Immunosuppressive drugs

Included in the formulation
  • Antilympholin
    lyophilizate d / infusion 
    RUSSIAN RESEARCH INSTITUTE OF GERONTOLOGY OF ROSZDRAVA, FGU     Russia
  • ATG-Fresenius C
    concentrate d / infusion 
    Fresenius Biotech GmbH     Germany
  • Atgam®
    concentrate d / infusion 
    Pharmacy and Upjohn Campani     USA
  • Timoglobulin®
    lyophilizate d / infusion 
    Genzyme Europe BV     Netherlands
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    L.04.A.A.04   Immunoglobulin antitimotsitarny (rabbit)

    Pharmacodynamics:

    Selective immunosuppressant with directed action against T-lymphocytes. Reduces the number of T-lymphocytes by recognizing the majority of molecules involved in the activation of T cells, which are involved in reactions of graft rejection. Does not affect the number of B-lymphocytes.

    Pharmacokinetics:

    After intravenous infusion, the concentration in the blood plasma is 10-40 μg / ml. By the end of the course of treatment (after 11 days), the minimum concentration IgG is 20-170 μg / ml, decreasing gradually within 2 months.

    Indications:

    It is used for the purpose of immunosuppression in organ transplantation for prevention and treatment of transplant rejection reactions.

    Used to treat aplastic anemia.

    ICD-10

    III.D60-D64   Aplastic and other anemia

    XXI.Z80-Z99.Z94   Presence of transplanted organs and tissues

    Contraindications:

    Acute and chronic infectious processes, individual intolerance.

    Carefully:

    With a second course of treatment, there is a risk of developing serum sickness.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intravenously, drip in an isotonic solution of sodium chloride or dextrose (50 ml per one vial of the drug).

    Prevention of rejection reactions

    By 1.25-2.5 mg / kg body weight for 1-3 weeks after liver, pancreas, kidney transplantation; for 11 days after cardiac transplantation.

    Treatment of the "graft versus host"

    2.5-5 mg / kg daily until improved laboratory and clinical signs.

    With aplastic anemia - 2.5-5 mg / kg daily for 5 days.

    The highest daily dose: 5 mg / kg body weight.

    The highest single dose: 5 mg / kg body weight.

    Side effects:

    Hemopoietic system: leukopenia, thrombocytopenia.

    Dermatological reactions: skin rash.

    Allergic reactions.

    Overdose:

    Lymphocytopenia, leukopenia, neutropenia, thrombocytopenia.

    Treatment - discontinuation of the drug, symptomatic therapy.

    Interaction:

    Simultaneous use with other immunosuppressors is dangerous development of immunodeficiency state.

    Contraindicated immunization with live attenuated vaccines, it is possible the development of generalized infections.

    Special instructions:

    Monitoring the number of lymphocytes and platelets. The drug is administered only in a hospital.

    Instructions
    Up